New analysis shows Victoza® is more effective when used early in the management of type 2 diabetes
3 October 2012 | By Novo Nordisk
"We know from clinical practice that liraglutide is highly effective..."
List view / Grid view
News
Sanofi and Bristol-Myers Squibb announce restructuring of alliance agreement
3 October 2012 | By Bristol-Myers Squibb Company
Sanofi & Bristol-Myers Squibb have restructured their long-term alliance...
TECAN and JPT Peptide Technologies announce cooperation agreement
2 October 2012 | By kdm communications limited
TECAN and JPT Peptide Technologies GmbH announced a collaborative agreement between the two specialist companies...
Investigational insulin degludec shows 43% lower rates of night-time hypoglycaemia
2 October 2012 | By Novo Nordisk
Than insulin glargine in a 2-year study investigating people with type 2 diabetes...
Lilly and Boehringer Ingelheim present health outcomes data for investigational novel basal insulin analogue
2 October 2012 | By Boehringer Ingelheim
Patient-reported health outcomes data from a Phase II study...
Clinical data for investigational SGLT2 inhibitor, empagliflozin*, demonstrates potential for oral treatment in type 2 diabetes
2 October 2012 | By Boehringer Ingelheim
Results of a pooled analysis...
Analyses presented at EASD support Trajenta® (linagliptin) as effective and well-tolerated for patients with type 2 diabetes with different background therapies
2 October 2012 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company today announced results from a large Phase III study and three pooled analyses of Phase III data presented at the 48th European Association for the Study of Diabetes (EASD) Annual Meeting, which support Trajenta® (linagliptin) as effective and well-tolerated for patients with type…
Roche’s trastuzumab emtansine (T-DM1) significantly extended survival in people with aggressive form of breast cancer
1 October 2012 | By Roche
Updated survival results from the Phase III EMILIA study...
Merck to present new data for VICTRELIS® (boceprevir) and MK-5172 at The AASLD 2012 Annual Meeting
1 October 2012 | By Merck
New data from Phase III studies...
Boehringer Ingelheim’s novel project transfer program enables fast track to launch for biopharmaceuticals
1 October 2012 | By Boehringer Ingelheim
Boehringer Ingelheim Biopharmaceuticals has installed a fast track process transfer...
Head-to-head study of GSK’s Votrient® vs sunitinib in advanced renal cell carcinoma meets primary endpoint
1 October 2012 | By GlaxoSmithKline
The pivotal Phase III study COMPARZ has met its primary endpoint...
Sanofi appoints Dr. Paul Chew, Chief Medical Officer and Head of Global Medical Affairs
1 October 2012 | By Sanofi
Sanofi is pleased to announce the appointment of Dr. Paul Chew...
Final analysis of Phase III HERA trial confirmed one year of Herceptin treatment as standard of care in early-stage HER2-positive breast cancer
1 October 2012 | By Roche
Final results from the Phase III HERA trial...
Novartis receives European Commission approval for once-daily Seebri® Breezhaler® as maintenance COPD treatment in the EU
1 October 2012 | By Novartis
Seebri® Breezhaler® approved...
New head of BASF unit Pharma Ingredients & Services
1 October 2012 | By BASF
As of October 1, Scott Thomson will assume the role of Senior Vice President...
